Peter García

Peter S.
García currently works at Moraga Biotechnology Corp., as Director and Bluejay Therapeutics, Inc., as Chief Financial Officer from 2024.
Mr. García also formerly worked at Noden Pharma USA, Inc., as Director, DURECT Corp., as Independent Director from 2021 to 2025, Amgen, Inc., as Principal, MDRNA, Inc., as Chief Financial Officer & Secretary in 2010, Lineage Cell Therapeutics, Inc., as CFO, Head-Investor & Media Relations from 2012 to 2013, Nuvelo, Inc., as Chief Financial Officer & Senior Vice President from 2001 to 2004, IntraBiotics Pharmaceuticals, Inc., as Chief Financial Officer from 1996 to 2004, Dendreon Corp., as Chief Financial Officer from 1996 to 2004, CYTYC Surgical Products, as Chief Financial Officer, Nanosys, Inc., as Chief Financial Officer from 2004 to 2008, Asterias Biotherapeutics, Inc., as Chief Financial Officer, Teradata Corp., as Principal, PDL BioPharma, Inc., as Chief Financial Officer & Vice President from 2013 to 2019, Adhera Therapeutics, Inc., as Chief Financial Officer, Secretary & IR Contact in 2011, Novacept, Inc., as Chief Financial Officer, and ALX Oncology Holdings, Inc., as Chief Financial Officer from 2021 to 2024.
Mr. García received his undergraduate degree in 1983 from Stanford University and Masters Business Admin degree in 1985 from the University of California, Los Angeles.